Neurological Manifestations of Chronic Methadone Maintenance Therapy: A Case Report and Literature Review

Ulviyya Gasimova ¹, Khurram M. Afzal ¹, Aninda B. Acharya ¹

¹. Neurology, Saint Louis University School of Medicine, St. Louis, USA

Corresponding author: Ulviyya Gasimova, ulviyya.gasimova@health.slu.edu

Abstract

Methadone is a long-acting opioid medication that is used as maintenance therapy for heroin addiction. We present a case of a patient on methadone maintenance therapy for chronic back pain who developed neurological complications. The patient presented with mental status changes and choreiform movements. Workup revealed lesions involving the subcortical white matter and basal ganglia. Choreiform movements improved after the initiation of treatment with topiramate, clonazepam, and risperidone. This combination was chosen as several prior case reports published significant benefit and improvement in choreiform movements with the mentioned regimen.

Introduction

Methadone (buprenorphine) is a synthetic long-acting opioid that is often used to treat heroin addiction and chronic pain [1]. Methadone is lipid-soluble and is known to act upon the limbic system and cerebellum, which have a high density of mu-opioid receptors [2-4]. Although it binds to the same receptors as other opioids, it does so more slowly and is less likely to lead to a euphoric sensation. As a result, methadone alleviates withdrawal and craving symptoms common in addiction to heroin and other opioids. Maintenance therapy with methadone due to uptake by brain tissues in the long term may affect neuromechanisms. The mechanism is mainly thought to be via dysregulation of gliogenesis [5].

Case Presentation

This is a case of a 40-year-old man who was independent at baseline. He was admitted to an outside hospital (OSH) with reported altered mental status. His medical history was notable for chronic back pain for which he was on long-standing (>5 years) methadone maintenance therapy. Comorbidities included chronic hepatitis C status post-treatment with a direct-acting antiviral medication years ago, as well as depression. Home medications included ferrous gluconate, fluticasone and salmeterol inhalers, aspirin, and methadone. He lived with his wife and daughter and was able to perform all his activities of daily life. His family reports that he had no premorbid cognitive impairment. The patient had no history of alcohol or drug use and quit smoking nine years ago after smoking two packs a day for 15 years.

He was in his usual state of health until a month ago prior to admission to an OSH. He awoke the morning of presentation to the OSH with altered level of consciousness, bilateral leg weakness, and urine incontinence. Workup at the OSH was notable for positive coronavirus variant 229E. Computed tomography (CT) of the chest, abdomen, and pelvis revealed patchy bilateral airspace infiltrates with scattered mediastinal lymph nodes, nonspecific bilateral punctate non-obstructing renal calyceal stones, and a small left inguinal hernia. Head CT was unremarkable. Magnetic resonance imaging (MRI) of the brain showed bilateral multiple small areas of deep white matter infarctions including left basal ganglia, globus pallidus, and bilateral subcortical white matter. His presentation was thought to be a result of metabolic or infectious etiology. He was discharged home with doxycycline, cefdinir, and atorvastatin. After discharge, his mental status and strength improved, but he did not return to his baseline.

Three days post-discharge, he had a recurrence of his decreased level of consciousness and was again admitted to the OSH. At the time, he was noted to have moderately increased creatinine levels. The repeated head CT did not reveal acute changes. He was then transferred to our institution.

On admission to our hospital, he was oriented to himself only, but not to place, date, or situation. He had non-fluent speech. The motor examination showed weakness and increased muscle tone in both legs. With arms held out, he was noted to have asterixis in both arms, more prominent on the right side. Muscle stretch reflexes showed increased reflexes in the lower extremity, as well as upgoing toes and sustained clonus bilaterally. Because of his mental status, the sensory examination was unreliable.
On hospital day 3, he was noted to have choreiform movements in his right arm and leg. Laboratory workup revealed a mildly elevated creatine kinase (CK). The urine drug screen was positive for methadone, but no other opioids. Further workup for metabolic, infectious, or inflammatory causes was unremarkable. Brain MRI with and without contrast was obtained, and the findings are discussed in Figures 1, 2, 3, 4.

**FIGURE 1:** DWI sequence with mild restricted diffusion and patchy non-mass-like enhancement at bilateral subcortical regions without mass effect (arrows).

DWI: diffusion-weighted imaging

**FIGURE 2:** DWI (left) and ADC (right) with basal ganglia, left more than right diffusion restriction with ADC correlate (arrows).

DWI: diffusion-weighted imaging; ADC: apparent diffusion coefficient
FIGURE 3: MRI of the brain T1 sequence axial images with and without contrast. Mild restricted diffusion and patchy non-mass-like enhancement in portions of this signal abnormality without mass effect (arrows).

MRI: magnetic resonance imaging

FIGURE 4: MRI of the brain T2/FLAIR sequence axial images with confluent white matter signal abnormality in bilateral frontoparietal and occipital white matter. Multiple small areas of cystic encephalomalacia in bilateral frontal and parietal deep white matter and bilateral globus pallidus (arrows).

MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery

Lumbar puncture with cerebrospinal fluid analysis for cell count, protein, glucose, infectious factors, cytology, autoimmune/inflammatory, and paraneoplastic workup was unrevealing. Continuous electroencephalogram (EEG) noted generalized slowing consistent with encephalopathy with no electrographic seizures. MRI of the cervical, thoracic, and lumbar spine did not show any significant abnormalities. For the choreiform movements, the patient was started on a regimen of topiramate 50 mg twice daily, clonazepam 0.5 mg thrice daily, and risperidone 0.5 mg at bedtime. The effect of topiramate on choreiform movements is associated with its effect on gamma-aminobutyric acid (GABA) activity and the modulation of voltage-gated ion channels, while risperidone works via the reduction dopaminergic pathway.
This helped the abnormal movements significantly, and he was discharged on this regimen to a rehabilitation facility.

**Discussion**

Prior studies investigated the neurotoxic effects of methadone on the central nervous system. In these studies, MRI findings were consistent with symmetric hyperintensities involving the cerebellum, basal ganglia, corona radiata, subcortical U fibers, and subcortical white matter [6-9]. Li et al. investigated the neurological consequences of chronic methadone consumption using diffusion tensor imaging. This group reported significantly decreased fractional anisotropy and axial diffusivity with increased radial diffusivity in extensive white matter regions alongside the involvement of the left posterior limb and internal capsule, superior and posterior corona radiata, bilateral external capsule, and right superior longitudinal fasciculus suggesting the neurotoxic effect of methadone in white matter tissues of the brain. Methadone toxicity has been reported to lead to cognitive dysfunction including alterations in memory, attention, visuospatial analysis, learning, and executive function [10-12].

Our patient presented with decreased level of consciousness, impaired attention, orientation, language, and memory. MRI revealed lesions in the cerebral white matter and basal ganglia. He had signs and symptoms consistent with pyramidal and extrapyramidal tract involvement.

**Conclusions**

Methadone is widely used in patients with heroin addiction, as well as in populations with chronic pain. However, in some cases, the risks and benefits of methadone usage are controversial. This case report highlights that methadone use can lead to extensive injury to the central nervous system, mostly involving white matter and basal ganglia. Long-term methadone use and its possible consequences should be discussed thoroughly with patients and family members.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**Acknowledgements**

We would like to thank Aninda B. Acharya, MD, for his assistance in reviewing this manuscript.

**References**

1. Mattick RP, Breen C, Kimber J, Devoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009, CD002209. 10.1002/14651858.CD002209.pub2
2. Corliss RF, Mandal R, Soriano BJ: Bilateral acute necrosis of the globi pallidi and rhabdomyolysis due to combined methadone and benzodiazepine toxicity. Am J Forensic Med Pathol. 2015, 34:1-4. 10.1097/PAF.0b013e31825a1b1e
3. Kuhar MJ, Pert CB, Snyder SH: Regional distribution of opiate receptor binding in monkey and human brain. Nature. 1973, 245:447-50. 10.1038/245447a0
4. Pertchuk LP, Sher JH, Ford DH: A morphological comparison of the regional distribution of methadone in human and rat brain as demonstrated by immunofluorescence. Drug Alcohol Depend. 1976, 1:247-54. 10.1016/0376-8716(76)90020-x
5. Stiene-Martin A, Knapp PE, Martin K, et al.: Opioid system diversity in developing neurons, astroglia and oligodendroglia in the subventricular zone and striatum: impact on gliogenesis in vivo. Glia. 2001, 36:78-88.
6. Corrêa J, Pillot J, Hilbert G: Methadone-induced toxic brain damage. Case Rep Radiol. 2013, 2013:602981. 10.1155/2013/602981
7. Cerese A, Leonini S, Bellini M, Chianese G, Venturi C: Methadone-induced toxic leukoencephalopathy: diagnosis and follow-up by magnetic resonance imaging including diffusion-weighted imaging and apparent diffusion coefficient maps. J Neuroimaging. 2011, 21:283-6. 10.1111/j.1552-6569.2010.00530.x
8. Salgado RA, Jorens PG, Baar I, Cras P, Hans G, Parizel PM: Methadone-induced toxic leukoencephalopathy: MR imaging and MR proton spectroscopy findings. AJNR Am J Neuroradiol. 2010, 31:563-6. 10.3174/ajnr.A1889
9. Bileviciute-Ljungar I, Häglund V, Carlsson J, von Heijne A: Regional distribution of methadone in the brain: MR imaging and MR proton spectroscopy findings. AJNR Am J Neuroradiol. 2010, 31:563-6. 10.3174/ajnr.A1889
10. Darke S, McDonald S, Kaye S, Torok M: Comparative patterns of cognitive performance amongst opioid maintenance patients, abstinent opioid users and non-opioid users. Drug Alcohol Depend. 2012, 126:309-15. 10.1016/j.drugalcdep.2012.05.052
11. Wang GY, Wouldes TA, Russell BR: Methadone maintenance treatment and cognitive function: a systematic review. Curr Drug Abuse Rev. 2013, 6:220-30. 10.2174/18744737112059990020
12. Li W, Li Q, Wang Y, et al.: Methadone-induced damage to white matter integrity in methadone maintenance patients: a longitudinal self-control DTI study. Sci Rep. 2016, 6:19662. 10.1038/srep19662